Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...
The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...
Just days after gaining similar regulatory approval in the USA, AstraZeneca and Amgen’s Tezspire (tezepelumab) has been ...
An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of ...
The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...
The nasal polyps market presents opportunities with multiple pipeline drugs in various development stages, targeting novel treatment approaches. Focused efforts by key players like AstraZeneca ...
SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...
Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...
The nose is the subject of many sayings. A measurement could be on the nose or an object right under your nose. You may be reminded to keep your nose clean and out of another’s affairs. While often ...
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback